One of the major problems in the treatment of cancer is the development of resistance to cytotoxic drugs. One mechanism of resistance, multidrug resistance (MDR), has been extensively studied in both animal and human cell lines in vitro (Biedler & Riehm, 1970; Fojo et al., 1985) , and is characterised by cross-resistance to a variety of structurally unrelated drugs following exposure to only one of them. The drugs involved in the MDR phenotype include anthracyclines and Vinca alkaloids (Moscow & Cowan, 1988) . The MDR phenotype is associated with increased expression of the MDR gene, mdr-1 (Roninson et al., 1986) , which encodes a transmembrane glycoprotein of 170,000 daltons (Riordan et al., 1985) . This glycoprotein, termed P-glycoprotein (P-gp), is present in many MDR cell lines, but not in the corresponding wild types (Juliano & Ling, 1976) and is thought to act as an energy-dependent drug efflux pump (Chen et al., 1986) . However, the role of the mdr-1 gene and P-gp in clinical drug resistance is not yet clear.
Human mdr-1 expression in a variety of normal tissues and tumours has been studied by measurement of mdr-1 mRNA (Fojo et al., 1987) . High levels were found in normal adrenal, kidney and colon and in tumours arising from these organs. Two previous studies have examined mdr-1 expression in breast cancer by measuring mdr-1 mRNA. In one series there was no expression (Merkel et al., 1989) while low levels were found in 15% of tumours in the other series (GoMOstein et al., 1989) . In contrast, we have previously shown significant levels of mdr-1 mRNA in a series of untreated primary breast cancers (Keith et al., 1990) Monoclonal antibodies have already been used to detect P-gp expression in several human tumours. C219, which reacts with an internal epitope of P-gp, has revealed P-gp expression in acute non-lymphoblastic leukaemia (Ma et al., 1987) as well as lung and ovarian carcinomas . Moreover, C219 has confirmed P-gp expression in both untreated and treated breast cancers (Salmon et al., 1989; Schneider et al., 1989 ). In addition MRK16, which reacts with an external epitope of P-gp, has detected P-gp expression by ICC in untreated lung and breast cancer (Sugawara et al., 1988) .
The use of ICC has therefore suggested that P-gp may be expressed in a small proportion of breast cancers although the number of tumours sampled is often small and may not be representative of all breast cancers. If present in breast cancer we need to establish which cells express P-gp and whether these cells are present prior to treatment with MDR drugs or whether they arise following exposure to them.
We have therefore further investigated P-gp expression in 29 primary breast cancers (all untreated) by ICC on tumour frozen sections using two monoclonal antibodies (C219 and MRK16) and an indirect alkaline phosphatase method.
Materials and methods

Human tissue
All breast biopsies were obtained from patients undergoing breast surgery at the Royal Infirmary, Glasgow from 1984 to 1986. All biopsies were snap frozen in liquid nitrogen and stored at -70°C until sectioning.
Cell line As a positive control with each specimen we used cytospin preparations of the small cell carcinoma of lung line H69/ LX10. This cell line was derived from the parent cell line NCI H69 by chronic exposure to adriamycin (to a final concentration of 1 Zg ml-') and was a gift from Dr P. Twentyman (MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge). It has previously been shown to have high expression of P-glycoprotein (Plumb et al., 1990) .
Immunohistochemistry
Cryostat sections of 5 ym were cut from each biopsy, air dried for 1 h, then fixed in acetone for 10 min at room temperature. They were then stained using an indirect immuno-alkaline phosphatase technique, incubating sections with a range of primary mouse monoclonal antibodies for 2 h (see below). The secondary antibody was a rabbit antimouse immunoglobulin conjugated to alkaline phosphatase (Dako, High Wycombe, Bucks., UK) and used at a working dilution of 1:20 for 45 min. The colour reaction was developed using a substrate solution based on fast red producing a red reaction in positive cells, then sections were counterstained with haematoxylin. This technique was chosen as we found it to be more sensitive than using immunoperoxidase and furthermore endogenous alkaline phosphatase activity can easily be blocked unlike endogenous peroxidase activity.
In negative controls an irrelevant monoclonal antibody (Clonab LN-C, Biotest, UK) was substituted for the primary antibody. For the detection of P-glycoprotein antibodies C219 ; obtained from CIS UK Ltd, High Wycombe, Bucks.) and MRK16 (Hamada & Tsuruo, 1986 ; a gift from T. Tsuruo) were used, both at a final concentration of 10 tg mlP'. Selected cases were also stained using CAM 5.2 (Becton Dickinson, California, USA), AE1/AE3 (ICN, High Wycombe, Bucks., UK) to detect cytokeratins and with antibody to vimentin (Boehringer, Lewes, East Sussex. UK). (Table I) . Immunostaining in epithelial cells, with both antibodies, occurred in either single cells (Figure 1 g ) or occasionally groups of cells (Figure ld) . In the presence of irrelevant antibody no areas of staining at all were visible. 
Discussion
In the present study we have examined P-glycoprotein expression by immunohistochemistry in 29 primary breast cancers (all untreated) using two monoclonal antibodies (C219 and MRK16) and an indirect alkaline phosphatase method. Our study clearly shows that P-glycoprotein immunoreactivity, detected by C219 and MRK16, can be demonstrated in a proportion of untreated primary breast cancers. Immunostaining was heterogeneous and interestingly appeared in epithelial and non-epithelial cells (Figure lc-f) . We have confirmed that the non-epithelial cells were of mesenchymal origin (Figure lh) and these are thought to be myofibroblasts.
Positive staining in epithelial cells with both C219 (21 of 29) and MRK16 (16 of 29) was detected in 1-9% of tumour cells in all but one tumour. This confirms two previous studies which found P-glycoprotein expression in one of nine (Sugawara et al., 1988) and two of twelve (Schneider et al., 1989 ) untreated breast cancers. The latter study considered staining in isolated cells to be negative, but it may be these cells which are selected following drug exposure, and are responsible for the development of clinical drug resistance. Our staining in epithelial cells was mostly membrane bound, although some cytoplasmic staining was seen, and these cells were confirmed as tumour cells by haematoxylin and eosin staining of a separate section from each tumour.
A surprising finding was the demonstration of P-glycoprotein immunoreactivity in stromal cells with both C219 (26 of 29) and MRK16 (12 of 29). The fact that stromal staining has been detected by two monoclonal antibodies (Figure le and f), which recognise different epitopes of P-glycoprotein, suggests that it is genuine expression of the protein. Staining in stromal cells has not previously been described in the literature although we are aware that one other group has detected expression in stromal cells by in situ hybridisation (Fojo, personal communication) . It has probably not been recognised previously as other studies have often used human breast cancer cell lines (Fairchild et al., 1987) or cytospin preparations of breast cancer cell suspensions (Salmon et al., 1989) to study P-glycoprotein expression. In all but one tumour, the percentage of stromal cells staining was always greater with C219 than with MRK16 (Table I) . Recent evidence has suggested that C219 may cross-react with the heavy chain of myosin in skeletal and cardiac muscle (Thiebaut et al., 1989) . Since it is well recognised that scirrhous carcinomas of the breast contain a population of stromal cells with characteristics of myofibroblasts (Tremblay, 1979) , and that explants of these cancers give rise to outgrowths of which > 90% are myofibroblasts (Barsky et al., 1984) , it is possible that our higher results with C219 are due to a cross-reaction with myosin. Alternatively C219 may be recognising a form of P-glycoprotein not detected by MRK16.
Previous studies with MRK16 have used formaldehyde fixation before immunocytochemistry, as cells fixed with acetone showed only weak localisation (Thiebaut et al., 1987) . It could be argued that this is one reason why our positive staining was usually less with MRK16 in both epithelial and stromal cells. However, we used acetone fixation for both C219 and MRK16 as our staining with both antibodies when present, was as distinct and as strong as our positive controls. We believe acetone-fixation has been successful with MRK16 in our study as the alkaline phosphatase method is particularly sensitive when compared with other immunohistochemical techniques.
The use of immunohistochemistry has allowed us to examine P-glycoprotein distribution within breast cancers and we have found heterogeneity of expression. This technique is extremely sensitive and can localise immunoreactivity in small numbers of single cells, unlike measurement of mdr-1 mRNA in whole tumours (Fojo et al., 1987) , which is less sensitive and can give rise to erroneous results because of tumour cell heterogeneity or expression in adjacent normal tissue.
There appear to be two mechanisms whereby tumours can become resistant to cytotoxic drugs. (Yusa & Tsuruo, 1989) are awaited.
In conclusion, we have demonstrated P-glycoprotein expression in primary breast cancers with no prior exposure to cytotoxic drugs. An interesting finding was expression in both epithelial and stromal cells. As immunocytochemistry can detect P-glycoprotein expression in single cells it is particularly useful where expression is heterogeneous, e.g. breast cancer, where MDR cells, when present, may only comprise a small percentage of the tumour cell population. It is hoped that this technique can be used to identify tumours with significant MDR expression so that MDR drugs can be avoided in treatment schedules or so that MDR modulators may be incorporated into the treatment of these tumours.
